Suboxone Addiction

Understanding buprenorphine-naloxone dependence, pharmacology, withdrawal, and evidence-based residential treatment at Phuket Island Rehab.

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.

Suboxone is a combination of buprenorphine, a high-affinity partial mu-opioid receptor agonist, and naloxone, an opioid antagonist included to deter injection. It is a life-saving medication for opioid use disorder, but it is also a long-acting opioid in its own right. Physical dependence on Suboxone is expected after weeks of daily use, and a smaller subset of patients develop a true substance use disorder around it: compulsive use, dose escalation, lost control, and misuse despite consequences. A properly supervised taper, supported by therapy and aftercare, is the safest way off. At Phuket Island Rehab, our medical detox is built around buprenorphine-experienced patients who are ready to step down from maintenance and rebuild life without daily opioids.

What is Suboxone?

Suboxone is the brand name for a sublingual film or sublingual tablet that combines two active ingredients: buprenorphine and naloxone. The U.S. Food and Drug Administration approved it in 2002 as a medication used to treat opioid use disorder. The buprenorphine component does the clinical work; the naloxone is added almost entirely to discourage people from dissolving and injecting the medication, because injected naloxone will precipitate drug withdrawal in someone with an opioid on board. Health professionals describe buprenorphine/naloxone as one of the cornerstone medications in modern opioid addiction treatment.

Buprenorphine alone is sold as Subutex, Sublocade (a once-monthly long-acting injection), Brixadi, and Belbuca (a buccal film for chronic pain). Generic buprenorphine-naloxone is now widely available. All of these are partial opioid agonists, more specifically partial mu-opioid receptor agonists. That single fact, more than anything else on the bottle, explains how Suboxone treats opioid addiction and how it can also produce addiction in its own right.

Suboxone is prescribed for two clinical reasons. The first is medical detoxification: short-term use, typically over a week or two, to bridge an opioid-dependent person off a short-acting opioid such as heroin, fentanyl, oxycodone, or hydrocodone with manageable opioid withdrawal symptoms. The second is maintenance treatment, sometimes called medication-assisted treatment, medication assisted treatment, or MAT, where the same person stays on a daily dose for months or years to help reduce cravings and prevent relapse. This is one of the medications used to treat opioid use disorder for the long term, alongside methadone or buprenorphine monotherapy. Both uses have strong evidence behind them. Both can also leave a patient physically dependent on Suboxone itself.

How buprenorphine works in the brain

The mu-opioid receptor sits on neurons throughout the brain and body. When a full agonist like heroin, morphine, or fentanyl binds to that receptor, the neuron is strongly inhibited, dopamine is released downstream in the reward circuit, and the user experiences analgesia, sedation, and euphoria. The same activation in the brainstem slows breathing. This is why fatal opioid overdoses are almost always respiratory deaths.

Buprenorphine binds to the same mu-opioid receptor but only partially activates it. The dose-response curve flattens out, so doubling the dose past a certain point does not double the effect. This ceiling, particularly on respiratory depression, is what makes buprenorphine safer than full agonists in overdose. It also has unusually high receptor affinity, which means it displaces other opioids and then holds the receptor for many hours. This explains the precipitated withdrawal that can occur when Suboxone is started too soon after a recent dose of heroin or fentanyl, and it is why timing matters during induction.

Buprenorphine has a long elimination half-life, generally between 24 and 42 hours, and an even longer pharmacological duration of action at the receptor. Most patients take it once daily, and a single missed dose rarely produces withdrawal. By contrast, heroin and fentanyl have short half-lives, which is part of why their withdrawal is more abrupt and brutal. The trade-off is that a Suboxone taper takes weeks, not days, precisely because the drug clears so slowly.

Why naloxone is in the formulation

Naloxone is the same drug used in Narcan, the rescue treatment for opioid overdose. When given by intramuscular or intranasal route to someone in respiratory arrest, it reverses overdose within minutes. In Suboxone, however, it is delivered under the tongue, where it is poorly absorbed and reaches the bloodstream only in trace amounts. Its job in the oral product is essentially to do nothing when taken correctly.

The naloxone becomes biologically active only if the film is crushed and injected. In that scenario, both buprenorphine and naloxone enter the bloodstream directly, and the naloxone outcompetes the buprenorphine at the receptor briefly enough to trigger withdrawal in an opioid-dependent person. This deterrent design is why Suboxone is the most common buprenorphine product prescribed in office-based settings, where diversion and injection risk are higher than in supervised clinics.

How Suboxone addiction develops

There is a clinical distinction between substance dependence and addiction that matters here. Dependence is a predictable physical adaptation: the body adjusts to daily opioid exposure, and stopping suddenly produces withdrawal. Almost everyone who takes Suboxone for more than two or three weeks becomes physically dependent. That is not a failure of treatment; it is the expected pharmacology. The risk of overdose also climbs in this period if the patient combines Suboxone with other drugs.

Addiction, by contrast, is defined behaviourally. The Diagnostic and Statistical Manual of Mental Disorders, fifth edition, classifies opioid use disorder by eleven criteria covering loss of control, craving, escalating use, use despite consequences, and social or occupational disruption. A patient who takes Suboxone exactly as prescribed, attends therapy, and rebuilds their life is dependent on the medication but does not meet criteria for ongoing opioid use disorder around the medication itself. A patient who chases higher doses, doctor-shops for additional prescriptions, uses non-prescribed Suboxone obtained on the street, or combines it with benzodiazepines and alcohol to amplify the effects of the drug is on a different trajectory. This kind of abuse of Suboxone is a form of abuse that often shadows recovery from heroin or fentanyl rather than replacing it cleanly.

Three patterns drive Suboxone misuse in practice. The first is dose escalation in patients with chronic untreated trauma, depression, or anxiety, who discover that higher doses dull emotional pain even when physical withdrawal is no longer the issue. The second is what clinicians sometimes call relapse-by-bridge: a patient who stops attending appointments but keeps using buprenorphine bought from non-medical sources, drifting into the same compulsive cycle they had with heroin. The third is intentional polydrug use, where Suboxone is combined with benzodiazepines, alcohol, gabapentin, or stimulants to produce an experience the prescribed dose alone does not.

Risk factors and signs of a problem

Risk for moving from controlled Suboxone use in a structured treatment program to disordered use is higher in patients with co-occurring stimulant use disorder, current benzodiazepine prescriptions, untreated post-traumatic stress disorder, prior drug overdose history, and unstable housing or employment. Diversion of Suboxone, meaning use of someone else’s prescription opioid or street-bought film, often begins as self-medication during a treatment gap and consolidates into a habit that no longer requires medical justification. Some patients describe slipping into trading one addiction for another, treating the buprenorphine the way they once treated a short-acting opioid rather than as part of opioid agonist therapy.

Behavioural signs that a patient or family member should not ignore include running out of medication early, requesting frequent dose increases, taking film at intervals that contradict the daily plan, combining Suboxone with sedatives or alcohol, hiding use from prescribing clinicians, lost prescriptions, and a return of preoccupation with dosing. Withdrawal symptoms between doses despite taking the prescribed amount are a separate clinical signal and usually indicate that the regimen needs review, not that the patient has relapsed.

Suboxone withdrawal

Stopping taking Suboxone abruptly after weeks or months of use produces a recognisable opioid withdrawal syndrome. Symptoms typically begin 24 to 72 hours after the last dose, because of buprenorphine’s long half-life, and run a longer but generally less peaked course than withdrawal from heroin or fentanyl. Most patients describe the physical phase as flu-like: muscle aches, joint pain, sweating, chills, gooseflesh, runny nose, watering eyes, abdominal cramping, diarrhoea, and yawning. These are the classic opioid withdrawal symptoms. Sleep collapses early and stays poor for weeks. Restless legs at night are almost universal. Tapering the dose under medical supervision avoids most of this. The risk of overdose rises sharply if the patient relapses to a short-acting opioid after a period of reduced tolerance.

The harder phase is usually the psychological one. Anhedonia, the inability to feel pleasure, settles in around the second week and can persist for one to three months. Anxiety, depressed mood, and cravings tend to surge in the second and third weeks rather than the first. This is the period in which unsupervised tapers most often fail, because the worst of the body symptoms have passed and the patient is left with a flat, irritable mood and a strong urge to dose.

Phase	Timing after last dose	Typical features
Acute physical	Day 1 to day 10	Muscle and joint pain, sweating, chills, runny nose, diarrhoea, yawning, restless legs, insomnia, cravings begin
Subacute	Day 7 to week 4	Sleep disturbance, low mood, anxiety, anhedonia, cravings peak, return of underlying mental health symptoms
Post-acute	Week 4 to month 3+	Persistent low energy, blunted reward, intermittent cravings, vulnerability to relapse and to alcohol or sedative misuse

Overdose, interactions, and the polydrug picture

Buprenorphine on its own is a relatively forgiving opioid in overdose because of the respiratory ceiling. The picture changes when other central nervous system depressants are involved. Benzodiazepines, alcohol, gabapentinoids, and z-drugs all act on overlapping inhibitory pathways. In combination with buprenorphine, they bypass the ceiling effect and produce the kind of deep sedation that ends in respiratory arrest. The U.S. Food and Drug Administration’s labelling on buprenorphine products carries a specific warning about benzodiazepine co-prescription, although the agency now advises that buprenorphine should not be withheld solely because a patient also takes a benzodiazepine.

Pharmacologically, buprenorphine is metabolised primarily by the CYP3A4 enzyme in the liver. Strong CYP3A4 inhibitors, including some HIV protease inhibitors, certain antifungals, and erythromycin-class antibiotics, can raise buprenorphine concentrations. Strong inducers such as rifampin and some anticonvulsants do the opposite and can precipitate withdrawal. Patients on multiple medications should bring a full list to every clinical visit rather than relying on the prescriber to ask.

Treatment at Phuket Island Rehab

Patients arrive at our centre for Suboxone treatment in three broad situations. Some have been on stable maintenance for years and are ready to taper off entirely. Some are using non-prescribed Suboxone alongside other substances and want to detox completely. Some are still using heroin, fentanyl, or prescription opioids and want a structured induction onto buprenorphine, followed by a planned step down. Each path requires a different sequencing of medication and therapy, and the first task of the admitting clinician is to read the patient honestly rather than fit them to a template. Our addiction treatment plan is built around the patient’s specific Suboxone use pattern rather than a generic protocol.

For patients tapering off Suboxone, our medical detox typically reduces the daily dose in steps spaced over one to three weeks, supported by clonidine for autonomic symptoms, non-opioid analgesia for muscle and joint pain, anti-emetics, and individualised sleep support. The pace is set by symptoms, not a calendar. Patients who have come from very high doses or long maintenance histories may step down more slowly. The clinical aim is to keep withdrawal tolerable, not absent. A withdrawal too smooth is usually a withdrawal that has not happened yet.

Therapy runs in parallel from day one. Detox is the medical task; recovery is the psychological one, and they cannot be sequenced. Patients work with our counsellors on the underlying pattern that brought them to opioids in the first place, on relapse prevention specific to post-buprenorphine vulnerability, on managing alcohol and drug use that often hides behind the opioid story, including alcohol and other drug use that has gone undeclared to previous prescribers, and on rebuilding the parts of life, work, relationships, sleep, that have been organised around dosing for years. Long-term recovery from opioid use disorder requires drug rehabilitation that addresses behaviour, mood, sobriety, and the underlying mental disorder when present, not just the pharmacology.

Why international clients come to Thailand

Patients from the United States, the United Kingdom, Australia, and Europe travel to Phuket Island Rehab for several reasons that are particular to opioid recovery. The first is full removal from the prescribing environment. A patient who has spent years collecting Suboxone prescriptions from the same clinic, in the same neighbourhood, alongside the same suppliers, may need geographic distance to make a real break. Thailand provides that without the cost or visibility of inpatient programmes at home.

The second is privacy. Many of our clients are professionals, executives, or public figures whose careers would not survive the kind of disclosure that comes with domestic rehab. Treatment in Phuket is discreet by default, and the climate, food, and pace of the island reduce the institutional feel that so many patients dread.

The third is cost. A month of structured residential care in Phuket, including medical detox, therapy, accommodation, food, and excursions, costs a fraction of the equivalent programme in the United States. For self-funded patients, that difference often means being able to commit to a longer stay, which is the single strongest predictor of long-term outcome in opioid use disorder.

When use of Suboxone has become more than prescribed

Many of the people who reach out to our team are not in obvious crisis. They are still functional, still showing up to work, still seeing the same prescriber. What has changed is that they no longer feel they are choosing the medication; the medication is choosing them. Dose increases happen and never quite reverse. The film comes out earlier in the day. A bad weekend ends with topping up from a friend’s prescription. Drinking is heavier than it used to be, and sleep is worse than it has been in years.

If that pattern is familiar, the question is no longer whether buprenorphine maintenance is appropriate. It is whether the current pattern is moving in the direction the patient wants their life to go. A conversation with an addiction specialist, a properly supervised taper, and time away from the environment that has shaped the habit are reasonable next steps, and they are not a failure of medication-assisted treatment. MAT works for many patients indefinitely. For others, it is a bridge, and bridges are designed to be crossed.

Summary

Suboxone is one of the most important medications in modern addiction medicine. It saves lives by stabilising opioid-dependent patients, reducing overdose risk, and giving the brain time to recover from years of high-potency opioid use. It is also a long-acting opioid that produces physical dependence, can be misused, and in a meaningful minority of patients becomes the substance use disorder rather than the treatment. The clinical task is not to decide whether the medication is good or bad, but to read the individual patient in front of you and to plan the next step, whether that is continued maintenance, a slower taper, a more intensive psychosocial wrap-around, or a residential detox away from the original prescribing environment.

As our counsellor Dr. Ponlawat Pitsuwan puts it, “The patients who do best on Suboxone are the ones who treat it as scaffolding around a life they are rebuilding, not as the building itself. When the scaffolding becomes the structure, it is time to talk about what comes next.”

Frequently asked questions

Is Suboxone addictive if it is supposed to treat addiction?

Suboxone produces physical dependence in almost everyone who takes it daily for more than a few weeks. That is not the same as addiction. Addiction, defined by the Diagnostic and Statistical Manual of Mental Disorders, requires a behavioural pattern of compulsive use, loss of control, and continued use despite harm. Most patients on stable, prescribed Suboxone are dependent but not addicted. A subset of patients does develop a substance use disorder around the medication, particularly when doses escalate, when use is combined with alcohol or benzodiazepines, or when prescriptions are obtained from multiple sources. The clinical answer is yes, Suboxone can be a substance of addiction, and the same medication that helps thousands of people every day can also become a problem in its own right. Misuse of Suboxone, sometimes called misuse Suboxone in the literature, is best understood as a form of opioid misuse rather than a separate phenomenon.

How long does Suboxone stay in your system?

Buprenorphine has an elimination half-life between roughly 24 and 42 hours, longer than almost any other commonly prescribed opioid. That means a single dose is still detectable in urine for around five to seven days in most patients, and longer in chronic users. Standard 5-panel drug tests do not pick up buprenorphine. It requires a specific buprenorphine assay or a 10-panel or 12-panel test designed to include it. Pharmacological duration of action at the receptor is longer than the plasma half-life, which is why most patients are stable on once-daily dosing.

What is the difference between Suboxone and Subutex?

Both products contain buprenorphine as the active opioid component. Suboxone is the two-active-ingredients product, combining buprenorphine and naloxone. Suboxone comes as a sublingual film or sublingual tablet, while Subutex is buprenorphine alone. The naloxone in Suboxone is essentially inert when the film is dissolved under the tongue but precipitates withdrawal if the product is crushed and injected, which is intended to reverse the effects of injection misuse. In current practice, Subutex is generally reserved for pregnant patients, where the naloxone exposure to the foetus is considered unnecessary, and for the small group of patients who cannot tolerate the naloxone component. Both produce the same dependence profile.

Can you overdose on Suboxone alone?

Buprenorphine has a ceiling effect on respiratory depression, which makes overdose from buprenorphine alone less likely than with full opioid agonists. Fatal overdoses on Suboxone almost always involve another central nervous system depressant: benzodiazepines, alcohol, z-drugs such as zolpidem, gabapentin, or pregabalin. When patients combine these with their buprenorphine, the ceiling effect no longer protects them. Patients on Suboxone should treat any sedating drug, prescribed or otherwise, as a potentially dangerous combination and disclose it to their prescriber.

How long does Suboxone withdrawal last?

The acute physical phase typically runs for seven to ten days, with peak symptoms between days three and five. A subacute phase of disturbed sleep, low mood, anxiety, and cravings runs through the rest of the first month. Post-acute symptoms, particularly anhedonia and intermittent cravings, can persist for two to three months. The duration depends on the dose at the time of discontinuation, the length of maintenance, the rate of taper, and whether the patient is medically supported. A planned taper, taken as prescribed and supervised by a clinician, produces a longer but much more tolerable withdrawal than abrupt cessation. Patients sometimes ask whether buprenorphine may safely be stopped without help; the answer in nearly all cases is no, and tapering the dose under medical supervision is the safer route. Helps reduce cravings and withdrawal symptoms during this period typically include clonidine, lofexidine, and adequate sleep support.

Do I need residential treatment, or can I taper from home?

Many stable, motivated patients with strong support successfully taper Suboxone in outpatient care. Residential treatment becomes the better option when previous outpatient attempts have stalled, when use of alcohol or other substances is part of the picture, when underlying mental health conditions are unstable, when the home environment was where the original opioid use developed, or when the patient simply needs to be removed from the prescribing relationship to make a clean break. The honest test is whether you can imagine yourself off Suboxone in the life you currently live. If the answer is no, residential treatment provides the time and distance to change the answer.

Sources

Substance Abuse and Mental Health Services Administration. Buprenorphine quick start guide and TIP 63: Medications for Opioid Use Disorder. samhsa.gov. The agency’s mental health services administration documents on the treatment of opioid use disorder, treatment for opioid dependence, and addiction to Suboxone draw on the same evidence base.

National Institute on Drug Abuse. Medications to treat opioid use disorder research report. nida.nih.gov.

U.S. Food and Drug Administration. Safety information on combined use of opioid medicines and benzodiazepines. fda.gov.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fifth edition, text revision. Opioid use disorder, criteria and severity ratings.

National Health Service. Buprenorphine for opioid dependence. nhs.uk.

World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. who.int.

Related reading on this site

• Buprenorphine vs Suboxone
• Is buprenorphine the same as Suboxone?
• Subutex pill
• Is Subutex stronger than Suboxone?
• Suboxone taper
• How to get off Suboxone
• Is Suboxone a narcotic?
• Suboxone abuse symptoms
• Signs of Suboxone abuse
• What happens if you take Suboxone too soon?
• Does Suboxone show up on a 12-panel drug test?
• Buprenorphine side effects
• Belbuca side effects
• Is Sublocade the same as Suboxone?
• Substitute for Suboxone
• Heroin addiction
• Medical detox at Phuket Island Rehab

Suboxone, buprenorphine, naloxone, buprenorphine/naloxone, Subutex, Sublocade, Brixadi, Belbuca, mu-opioid receptor, opioid receptor, opioid agonist therapy, partial opioid agonist, ceiling effect, precipitated withdrawal, CYP3A4, opioid use disorder, opioid addiction, opioid dependence, substance dependence, substance abuse, opiate, prescription drug, sublingual tablet, sublingual film, DSM-5, medication-assisted treatment, medication assisted treatment, MAT, naltrexone, methadone, clonidine, Narcan, polydrug use, benzodiazepines, alcohol use disorder, anhedonia, post-acute withdrawal, drug withdrawal, drug overdose, drug detoxification, drug rehabilitation, drug tolerance, dose (biochemistry), pharmacodynamics, signs and symptoms, euphoria, euphoric, sobriety, psychotherapy, mental disorder, mental health, U.S. Food and Drug Administration, SAMHSA, National Institute on Drug Abuse, National Health Service, World Health Organization, Phuket Island Rehab.